Cargando…
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
A European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry and 2 clinicians who were representatives of ESMO. The focus of the meeting was exclusively on the intratumo...
Autores principales: | Marabelle, A, Andtbacka, R, Harrington, K, Melero, I, Leidner, R, de Baere, T, Robert, C, Ascierto, P A, Baurain, J -F, Imperiale, M, Rahimian, S, Tersago, D, Klumper, E, Hendriks, M, Kumar, R, Stern, M, Öhrling, K, Massacesi, C, Tchakov, I, Tse, A, Douillard, J -Y, Tabernero, J, Haanen, J, Brody, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290929/ https://www.ncbi.nlm.nih.gov/pubmed/30295695 http://dx.doi.org/10.1093/annonc/mdy423 |
Ejemplares similares
-
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020) -
Repurposing infectious disease vaccines for intratumoral immunotherapy
por: Melero, Ignacio, et al.
Publicado: (2020) -
Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice
por: Meyblum, Louis, et al.
Publicado: (2023) -
Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
por: Tselikas, Lambros, et al.
Publicado: (2020) -
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
por: Curti, Brendan D, et al.
Publicado: (2022)